 | • レポートコード：MRC2301F0025 • 出版社/出版日：Transparency Market Research / 2022年10月4日 • レポート形態：英文、PDF、211ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| トランスペアレンシー・マーケット・リサーチ社の当調査資料では、世界のペプチド治療薬市場について総合的に調査・分析を行い、序論、仮定・調査手法、市場概要、主要インサイト、用途別（癌、メタボリック、CVD、呼吸器、その他）分析、投与経路別（非経口、経口）分析、種類別（イノベーティブ、ジェネリック）分析、技術別（液相、固相、ハイブリッド相）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ）分析、競争状況、企業情報などの項目を掲載しています。なお、当市場の主要企業には、Amgen, Inc.、Bachem Holding AG、Eli Lilly and Company、F. Hoffmann-La Roche Ltd.、GlaxoSmithKline plc、Novartis AG、Pfizer, Inc.、Sanofi、Takeda Pharmaceutical Company Limited、Teva Pharmaceutical Industries Ltd.などが含まれています。 ・序論 ・仮定・調査手法 ・市場概要 ・主要インサイト ・世界のペプチド治療薬市場規模：用途別 - 癌における市場規模 - メタボリックにおける市場規模 - CVDにおける市場規模 - 呼吸器における市場規模 - その他用途における市場規模 ・世界のペプチド治療薬市場規模：投与経路別 - 非経口投与の市場規模 - 経口投与の市場規模 ・世界のペプチド治療薬市場規模：種類別 - イノベーティブ医薬品の市場規模 - ジェネリック医薬品の市場規模 ・世界のペプチド治療薬市場規模：技術別 - 液相技術の市場規模 - 固相技術の市場規模 - ハイブリッド相技術の市場規模 ・世界のペプチド治療薬市場規模：地域別 - 北米のペプチド治療薬市場規模 - ヨーロッパのペプチド治療薬市場規模 - アジア太平洋のペプチド治療薬市場規模 - 中南米のペプチド治療薬市場規模 - 中東/アフリカのペプチド治療薬市場規模 ・競争状況 ・企業情報 |
Peptide Therapeutics Market – Scope of Report
TMR’s report on the global peptide therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global peptide therapeutics market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global peptide therapeutics market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the peptide therapeutics market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global peptide therapeutics market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global peptide therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global peptide therapeutics market.
The report delves into the competitive landscape of the global peptide therapeutics market. Key players operating in the global peptide therapeutics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global peptide therapeutics market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market peptide therapeutics.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Peptide Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Peptide Therapeutics Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. White Space Analysis
5.2. Porter’s Analysis
5.3. Pipeline Analysis (Phase III)
5.4. Peptide Drug Chemical Structure Trend Analysis
5.5. Separation Media for Peptide Drug Manufacturing
5.6. Covid-19 Impact Analysis
6. Global Peptide Therapeutics Market Analysis and Forecast, by Application
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Application, 2017–2031
6.3.1. Cancer
6.3.2. Metabolic
6.3.3. CVD
6.3.4. Respiratory
6.3.5. GIT
6.3.6. Anti-infective
6.3.7. Dermatology
6.3.8. CNS
6.3.9. Renal
6.4. Market Attractiveness Analysis, by Application
7. Global Peptide Therapeutics Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2031
7.3.1. Parenteral
7.3.2. Oral
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Peptide Therapeutics Market Analysis and Forecast, by Type
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Type, 2017–2031
8.3.1. Innovative
8.3.2. Generic
8.4. Market Attractiveness Analysis, by Type
9. Global Peptide Therapeutics Market Analysis and Forecast, by Technology
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Technology, 2017–2031
9.3.1. Liquid Phase
9.3.2. Solid Phase
9.3.3. Hybrid Phase
9.4. Market Attractiveness Analysis, by Technology
10. Global Peptide Therapeutics Market Analysis and Forecast, by Type of Molecule
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast, by Type of Molecule, 2017–2031
10.3.1. Vasopressin
10.3.2. Somatostatin
10.3.3. Calcitonin
10.3.4. Natriuretic
10.4. Market Attractiveness Analysis, by Type of Molecule
11. Global Peptide Therapeutics Market Analysis and Forecast, by API Peptide Type
11.1. Introduction & Definition
11.2. Key Findings / Developments
11.3. Market Value Forecast, by API Peptide Type ,2017–2031
11.3.1. In-house
11.3.2. CMO
11.4. Market Attractiveness Analysis, by API Peptide Type
12. Global Peptide Therapeutics Market Analysis and Forecast, by Region
12.1. Key Findings
12.2. Market Value Forecast, by Region
12.2.1. North America
12.2.2. Europe
12.2.3. Asia Pacific
12.2.4. Latin America
12.2.5. Middle East & Africa
12.3. Market Attractiveness Analysis, by Region
13. North America Peptide Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Application,2017–2031
13.2.1. Cancer
13.2.2. Metabolic
13.2.3. CVD
13.2.4. Respiratory
13.2.5. GIT
13.2.6. Anti-infective
13.2.7. Dermatology
13.2.8. CNS
13.2.9. Renal
13.3. Market Value Forecast, by End-user,2017–2031
13.3.1. Parenteral
13.3.2. Oral
13.4. Market Value Forecast, by Type, 2017–2031
13.4.1. Innovative
13.4.2. Generic
13.5. Market Value Forecast, by Technology, 2017–2031
13.5.1. Liquid Phase
13.5.2. Solid Phase
13.5.3. Hybrid Phase
13.6. Market Value Forecast, by Type of Molecule, 2017–2031
13.6.1. Vasopressin
13.6.2. Somatostatin
13.6.3. Calcitonin
13.6.4. Natriuretic
13.7. Market Value Forecast, by API Peptide Type, 2017–2031
13.7.1. In-house
13.7.2. CMO
13.8. Market Value Forecast, by Country, 2017–2031
13.8.1. U.S.
13.8.2. Canada
13.9. Market Attractiveness Analysis
13.9.1. By Application
13.9.2. By Route of Administration
13.9.3. By Type
13.9.4. By Technology
13.9.5. By Type of Molecule
13.9.6. By API Peptide Type
13.9.7. By Country
14. Europe Peptide Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Application, 2017–2031
14.2.1. Cancer
14.2.2. Metabolic
14.2.3. CVD
14.2.4. Respiratory
14.2.5. GIT
14.2.6. Anti-infective
14.2.7. Dermatology
14.2.8. CNS
14.2.9. Renal
14.3. Market Value Forecast, by End-user, 2017–2031
14.3.1. Parenteral
14.3.2. Oral
14.4. Market Value Forecast, by Type, 2017–2031
14.4.1. Innovative
14.4.2. Generic
14.5. Market Value Forecast, by Technology, 2017–2031
14.5.1. Liquid Phase
14.5.2. Solid Phase
14.5.3. Hybrid Phase
14.6. Market Value Forecast, by Type of Molecule, 2017–2031
14.6.1. Vasopressin
14.6.2. Somatostatin
14.6.3. Calcitonin
14.6.4. Natriuretic
14.7. Market Value Forecast, by API Peptide Type, 2017–2031
14.7.1. In-house
14.7.2. CMO
14.8. Market Value Forecast, by Country/Sub-region, 2017–2031
14.8.1. Germany
14.8.2. U.K.
14.8.3. France
14.8.4. Spain
14.8.5. Italy
14.8.6. Rest of Europe
14.9. Market Attractiveness Analysis
14.9.1. By Application
14.9.2. By Route of Administration
14.9.3. By Type
14.9.4. By Technology
14.9.5. By Type of Molecule
14.9.6. By API Peptide Type
14.9.7. By Country/Sub-region
15. Asia Pacific Peptide Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Application, 2017–2031
15.2.1. Cancer
15.2.2. Metabolic
15.2.3. CVD
15.2.4. Respiratory
15.2.5. GIT
15.2.6. Anti-infective
15.2.7. Dermatology
15.2.8. CNS
15.2.9. Renal
15.3. Market Value Forecast, by End-user, 2017–2031
15.3.1. Parenteral
15.3.2. Oral
15.4. Market Value Forecast, by Type, 2017–2031
15.4.1. Innovative
15.4.2. Generic
15.5. Market Value Forecast, by Technology, 2017–2031
15.5.1. Liquid Phase
15.5.2. Solid Phase
15.5.3. Hybrid Phase
15.6. Market Value Forecast, by Type of Molecule, 2017–2031
15.6.1. Vasopressin
15.6.2. Somatostatin
15.6.3. Calcitonin
15.6.4. Natriuretic
15.7. Market Value Forecast, by API Peptide Type, 2017–2031
15.7.1. In-house
15.7.2. CMO
15.8. Market Value Forecast, by Country/Sub-region, 2017–2031
15.8.1. China
15.8.2. Japan
15.8.3. India
15.8.4. Australia & New Zealand
15.8.5. Rest of Asia Pacific
15.9. Market Attractiveness Analysis
15.9.1. By Application
15.9.2. By Route of Administration
15.9.3. By Type
15.9.4. By Technology
15.9.5. By Type of Molecule
15.9.6. By API Peptide Type
15.9.7. By Country/Sub-region
16. Latin America Peptide Therapeutics Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Application, 2017–2031
16.2.1. Cancer
16.2.2. Metabolic
16.2.3. CVD
16.2.4. Respiratory
16.2.5. GIT
16.2.6. Anti-infective
16.2.7. Dermatology
16.2.8. CNS
16.2.9. Renal
16.3. Market Value Forecast, by End-user, 2017–2031
16.3.1. Parenteral
16.3.2. Oral
16.4. Market Value Forecast, by Type, 2017–2031
16.4.1. Innovative
16.4.2. Generic
16.5. Market Value Forecast, by Technology,2017–2031
16.5.1. Liquid Phase
16.5.2. Solid Phase
16.5.3. Hybrid Phase
16.6. Market Value Forecast, by Type of Molecule, 2017–2031
16.6.1. Vasopressin
16.6.2. Somatostatin
16.6.3. Calcitonin
16.6.4. Natriuretic
16.7. Market Value Forecast, by API Peptide Type, 2017–2031
16.7.1. In-house
16.7.2. CMO
16.8. Market Value Forecast, by Country/Sub-region, 2017–2031
16.8.1. Brazil
16.8.2. Mexico
16.8.3. Rest of Latin America
16.9. Market Attractiveness Analysis
16.9.1. By Application
16.9.2. By Route of Administration
16.9.3. By Type
16.9.4. By Technology
16.9.5. By Type of Molecule
16.9.6. By API Peptide Type
16.9.7. By Country/Sub-region
17. Middle East & Africa Peptide Therapeutics Market Analysis and Forecast
17.1. Introduction
17.1.1. Key Findings
17.2. Market Value Forecast, by Application, 2017–2031
17.2.1. Cancer
17.2.2. Metabolic
17.2.3. CVD
17.2.4. Respiratory
17.2.5. GIT
17.2.6. Anti-infective
17.2.7. Dermatology
17.2.8. CNS
17.2.9. Renal
17.3. Market Value Forecast, by End-user, 2017–2031
17.3.1. Parenteral
17.3.2. Oral
17.4. Market Value Forecast, by Type, 2017–2031
17.4.1. Innovative
17.4.2. Generic
17.5. Market Value Forecast, by Technology, 2017–2031
17.5.1. Liquid Phase
17.5.2. Solid Phase
17.5.3. Hybrid Phase
17.6. Market Value Forecast, by Type of Molecule, 2017–2031
17.6.1. Vasopressin
17.6.2. Somatostatin
17.6.3. Calcitonin
17.6.4. Natriuretic
17.7. Market Value Forecast, by API Peptide Type, 2017–2031
17.7.1. In-house
17.7.2. CMO
17.8. Market Value Forecast, by Country/Sub-region, 2017–2031
17.8.1. GCC Countries
17.8.2. South Africa
17.8.3. Rest of Middle East & Africa
17.9. Market Attractiveness Analysis
17.9.1. By Application
17.9.2. By Route of Administration
17.9.3. By Type
17.9.4. By Technology
17.9.5. By Type of Molecule
17.9.6. By API Peptide Type
17.9.7. By Country/Sub-region
18. Competition Landscape
18.1. Market Player – Competition Matrix (by tier and size of companies)
18.2. Market Share Analysis, by Company, 2021
18.3. Company Profiles
18.3.1. Amgen, Inc.
18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.1.2. Product Portfolio
18.3.1.3. SWOT Analysis
18.3.1.4. Strategic Overview
18.3.2. Bachem Holding AG
18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.2.2. Product Portfolio
18.3.2.3. SWOT Analysis
18.3.2.4. Strategic Overview
18.3.3. Eli Lilly and Company
18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.3.2. Product Portfolio
18.3.3.3. SWOT Analysis
18.3.3.4. Strategic Overview
18.3.4. F. Hoffmann-La Roche Ltd.
18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.4.2. Product Portfolio
18.3.4.3. SWOT Analysis
18.3.4.4. Strategic Overview
18.3.5. GlaxoSmithKline plc
18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.5.2. Product Portfolio
18.3.5.3. SWOT Analysis
18.3.5.4. Strategic Overview
18.3.6. Novartis AG
18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.6.2. Product Portfolio
18.3.6.3. SWOT Analysis
18.3.6.4. Strategic Overview
18.3.7. Pfizer, Inc.
18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.7.2. Product Portfolio
18.3.7.3. SWOT Analysis
18.3.7.4. Strategic Overview
18.3.8. Sanofi
18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.8.2. Product Portfolio
18.3.8.3. SWOT Analysis
18.3.8.4. Strategic Overview
18.3.9. Takeda Pharmaceutical Company Limited
18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.9.2. Product Portfolio
18.3.9.3. SWOT Analysis
18.3.9.4. Strategic Overview
18.3.10. Teva Pharmaceutical Industries Ltd.
18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.10.2. Product Portfolio
18.3.10.3. SWOT Analysis
18.3.10.4. Strategic Overview
